Abstract: An antenna is provided in this application. The antenna includes multiple radiating units, at least two adjacent radiating units are correspondingly provided with a respective decoupling structure, the decoupling structure includes two microstrip line units, one microstrip line unit of the two microstrip line units includes at least one microstrip line, and the two microstrip line units are located on two opposite sides of two radiating units in a direction perpendicular to an arrangement direction of two adjacent radiating units. According to the antenna provided in the embodiments of the present disclosure, the decoupling structure composed of the microstrip line are disposed on two sides of the at least two adjacent radiating units, so that an indirect coupling field is formed by the decoupling structure, and the indirect coupling field counteracts a direct coupling field between adjacent radiating units.

Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?V-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.

Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.

Abstract: The present invention relates to an aryl amide compound of formula (I?), a pharmaceutical composition comprising same, a preparation method therefor, and the use thereof for preventing or treating tumor-related diseases or conditions.

Abstract: A method for stably storing an isocyanate composition comprising A1) one or more polyisocyanates and A2) at least one free radical initiator is provided. The method comprises adding a component A3) comprising at least one free radical inhibitor into the isocyanate composition. An isocyanate composition and a polyurethane resin prepared from the isocyanate composition is also provided.

Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.

Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

Abstract: A method for preparing a polyurethane composite by a vacuum infusion process, a polyurethane composite prepared by said method and use thereof. The method for preparing a polyurethane composite by a vacuum infusion process of the present invention can reduce raw materials and production costs.

Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

Abstract: The present disclosure relates to a heterocyclic compound, a pharmaceutical composition comprising same, a preparation method therefor, and a use thereof. Specifically, the compound of the present invention is represented by formula (I), and used for preventing or treating a disease or condition related to RET activity.

Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

Abstract: The invention relates to a method for preparing a polyurethane composite by vacuum infusion process, the composite prepared by the method and use thereof. The method according to the present invention preferably comprises the use of a polyester peel ply having a specific gram weight, a reinforced material and/or a porous medium, and the like. The polyurethane composite produced by the method according to the present invention has both good physical properties and a satisfactory outer surface without the need to separately treat the outer surface.

Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?V-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: The present invention relates to a composite wind turbine blade, manufacturing method and application thereof. The blade comprises blade shell, shear web, spar cap and blade root, wherein the spar cap is manufactured with polyurethane resin and the blade shell is manufactured with epoxy resin. The present invention contributes to increasing stiffness of the wind turbine blade, making the wind turbine blade lighter and shortening its production cycle, thus saving manufacturing cost thereof.